Registration Dossier
Registration Dossier
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 603-373-3 | CAS number: 129909-90-6
Toxicological Summary
Administrative data
Workers - Hazard via inhalation route
Systemic effects
Long term exposure
- Hazard assessment conclusion:
- DNEL (Derived No Effect Level)
- Value:
- 0.16 mg/m³
- Most sensitive endpoint:
- carcinogenicity
DNEL related information
- Overall assessment factor (AF):
- 12.5
- Modified dose descriptor starting point:
- NOAEC
Acute/short term exposure
- Hazard assessment conclusion:
- DNEL (Derived No Effect Level)
- Value:
- 0.704 mg/m³
- Most sensitive endpoint:
- neurotoxicity
DNEL related information
- Overall assessment factor (AF):
- 12.5
- Modified dose descriptor starting point:
- NOAEC
Local effects
Long term exposure
- Hazard assessment conclusion:
- DNEL (Derived No Effect Level)
- Value:
- 0.16 mg/m³
- Most sensitive endpoint:
- carcinogenicity
DNEL related information
- Overall assessment factor (AF):
- 12.5
- Dose descriptor:
- NOAEC
Acute/short term exposure
- Hazard assessment conclusion:
- DNEL (Derived No Effect Level)
- Value:
- 0.704 mg/m³
- Most sensitive endpoint:
- neurotoxicity
DNEL related information
- Overall assessment factor (AF):
- 12.5
- Dose descriptor starting point:
- NOAEC
Workers - Hazard via dermal route
Systemic effects
Long term exposure
- Hazard assessment conclusion:
- DNEL (Derived No Effect Level)
- Value:
- 20 mg/kg bw/day
- Most sensitive endpoint:
- repeated dose toxicity
DNEL related information
- Overall assessment factor (AF):
- 50
- Modified dose descriptor starting point:
- NOAEL
Acute/short term exposure
- Hazard assessment conclusion:
- DNEL (Derived No Effect Level)
- Value:
- 20 mg/kg bw/day
- Most sensitive endpoint:
- repeated dose toxicity
DNEL related information
- Overall assessment factor (AF):
- 50
- Modified dose descriptor starting point:
- NOAEL
Local effects
Long term exposure
- Hazard assessment conclusion:
- DNEL (Derived No Effect Level)
- Value:
- 0.584 mg/cm²
- Most sensitive endpoint:
- repeated dose toxicity
DNEL related information
- Overall assessment factor (AF):
- 12.5
- Dose descriptor:
- other: NOAEL
Acute/short term exposure
- Hazard assessment conclusion:
- DNEL (Derived No Effect Level)
- Value:
- 0.584 mg/cm²
- Most sensitive endpoint:
- repeated dose toxicity
DNEL related information
- Overall assessment factor (AF):
- 12.5
- Dose descriptor starting point:
- other: NOAEL
Workers - Hazard for the eyes
Additional information - workers
ACUTE:
Table 7-1:Available acute dose descriptors per endpoint for MKH 3586 as a result of its hazard assessment
Endpoint |
Quantitative dose descriptor (appropriate unit) or qualitative assessment |
Associated relevant effect |
Remarks on study |
||
Local |
Systemic |
||||
Acute toxicity |
oral |
NA |
NOAEL |
Local: no effects Systemic: Ptosis, decreased approach response, nasal staining |
Acute rat neurotoxicity study |
dermal |
NOAEL |
NOAEL 1000 mg/kg |
Local: No observed effect Systemic: No observed effect |
28 day rat dermal study |
|
inhalation |
Not tested |
- |
- |
- |
|
Acute and repeat (sub-acute, sub-chronic, chronic) dermal:
Local-
Dose descriptor selection: from the sub-chronic dermal toxicity study no local effects were observed up to the limit dose (1000 mg/kg/day). The NOAEL value was converted to mg/cm2value based on the quantity of test material applied to the test area of skin (for the repeat dermal rat study a dose area of no less than 10% of the total body surface area (TBSA) was used. The 10% TBSA was considered equivalent to 36 cm2(<250g); 40 cm2(251-300g); 44 cm2(301-350g); 48 cm2(351-400g); 52 cm2(401-450g); 56 cm2(451-500g). For the purposes of DNEL setting the following values for both weight and 10% TBSA were used: 351g and 48 cm2, respectively.
NOAEL = dose (mg/kg bw) * bw (g) / 1000g / skin area (cm2).
Sub-acute NOAEL = 1000 mg/kg bw * 351g / 1000g / 48 cm2
Corrected sub-acute NOAEC (local) = 7.3 mg/cm2
Dose response: no local effects were observed up to the maximum dose tested, 1000 mg/kg/day (i.e. the NOAEL).
AF: default AFs were applied, according to the guidance in Chapter R.8 (note allometric scaling not relevant for local effects).
AF = Interspecies * Intraspecies (worker) * Exposure duration * Dose-response * Quality of whole database
AF = 2.5 * 5 * 1 * 1 *1 = 12.5
DNEL derivation: NOAEC / AF
Repeat (sub-acute, sub-chronic, chronic) DNEL dermal local DNEL = 7.3 mg/cm2/ 12.5 = 0.584 mg/cm2
Systemic-
Dose descriptor selection: the lowest reliable dose descriptor was selected from the sub-acute (21 day) dermal study.
Dose response: no systemic effects were observed up to the maximum dose tested, 1000 mg/kg/day (i.e. the NOAEL).
AF: default AFs were applied, according to the guidance in Chapter R.8.
AF = Interspecies (including allometric scaling for rabbit to human) * Intraspecies (worker) * Exposure duration * Dose-response * Quality of whole database
AF = 2.5 *(4) * 5 * 1 *1 *1 = 50
DNEL derivation: NOAEL / AF
- Repeat (sub-acute, sub-chronic, chronic) DNEL dermal systemic = 1000 mg/kg / 50 = 20 mg/kg
From the available acute and sub-acute dermal toxicity data the duration of the study does not markedly increase the local or systemic effects, implying that dermal absorption is minimal. Therefore, the acute DNELs for local and systemic effects are considered applicable for the both a sub-chronic and chronic exposure scenario without the need to apply further AF for duration extrapolation.
Acute inhalation:
Local and systemic -
Dose descriptor selection: in the acute inhalation study no local effects associated with respiratory irritation or evidence of systemic toxicity were observed immediately after dosing or up 14 day post dosing in this limit study. As there are deficiencies recognised in the study design (i.e. no true NOAEL identified), in accordance with the guidance oral data is available from the acute neurotoxicity study where complete neuro-histopathology was undertaken. The NOAEL derived from this study was in agreement with the NOAEL derived from the two-generation (6.4 mg/kg) and developmental study (15 mg/kg).
The acute oral neurotoxicity value was corrected in accordance with guidance (Chapter R.8) for route to route (oral to inhalation conversion):
Corrected: NOAEC = oral NOAEL * 1 / rat resp. volume (0.38 m3[8 hr]) * oral (50% default) / inhalation absorption (100% default) * human resting resp. volume (6.7 m3[8 hr]) / worker resp. volume (10 m3[8 hr])
Acute = NOAEL = 10 mg/kg (NOAEL from acute oral neurotoxicity)
Corrected acute NOAEC = 8.8 mg/m3
Dose response: the systemic effects observed in the acute oral neurotoxicity study were deemed to have a threshold mechanism. AF were applied according to the guidance in Chapter R.8.
AF: default AFs were applied, according to the guidance in Chapter R.8 (note allometric scaling not relevant for the inhalatory route of exposure). Due to the lack of detailed histopathology and only LD50value established in the acute inhalatory study:
AF = Interspecies * Intraspecies (worker) * Exposure duration * Dose-response * Quality of whole database
AF = 2.5 * 5 * 1 * 1 * 1 = 12.5
DNEL deviation: Corrected NOAEC / AF
- Acute DNEL inhalation local & systemic = 8.8 mg/m3/ 12.5 = 0.704 mg/m3
Table 7-2:Acute DNELs for workers
Endpoint Specific DNELs for Workers |
||||||
Endpoint |
Corrected dose-descriptor |
Overall AF |
Endpoint Specific DNEL |
|||
Local |
Systemic |
Local |
Systemic |
|||
Acute toxicity |
Oral |
Not required |
Not required |
- |
- |
- |
Derm |
NOAEL 7.3 mg/cm2 |
NOAEL 1000 mg/kg |
Local 12.5 |
0.584 mg/cm2 |
20 mg/kg |
|
Inhal |
- |
NOAEC |
Local / systemic 12.5 |
0.704 mg/m3 |
0.704 mg/m3 |
|
REPEAT:
Table 7-3:Available repeat dose descriptors per endpoint for MKH 3586 as a result of its hazard assessment
Endpoint |
Quantitative dose descriptor (appropriate unit) or qualitative assessment |
Associated relevant effect |
Remarks on study |
||
Local |
Systemic |
||||
Repeated dose toxicity sub-acute/ sub-chronic/ chronic |
oral |
NA |
NOAEL |
Local: no effects Systemic: Increased liver weights and biochemical changes (increases in T3, T4 and serum cholesterol) |
Chronic phase of 2 year rat combined chronic/ carcinogenicity study |
dermal |
NOAEL 1000 mg/kg |
NOAEL 1000 mg/kg |
Local: 12.5 Systemic: 50 |
21 day dermal toxicity study |
|
dermal |
Not tested |
- |
- |
- |
|
Inhalation (sub acute) |
Not tested |
- |
- |
- |
|
Inhalation (sub-chronic / chronic) |
Not tested |
- |
- |
- |
|
Repeat (chronic) dermal:
Refer to the Acute section (above)
Repeat (chronic) inhalation:
Local / systemic -
Dose descriptor selection: no repeat dose inhalation study was available, therefore the calculated NOAEC for the inhalatory route has been derived from the guidance for route to route (oral to inhalation) conversion in Chapter R.8 which incorporates a conversion for rat to human respiration volume and an adjustment for work respiration volume.
As oral data is available for sub-acute, sub-chronic and chronic durations, in accordance with the guidance, the chronic oral study is the preferred starting point, with no AF for duration extrapolation required. In this case the NOAEL from the 1 year rat dietary study was used.
Corrected: NOAEC = oral NOAEL * 1 / rat resp. volume (0.38 m3[8 hr]) * oral (50% default) / inhalation absorption (100% default) * human resting resp. volume (6.7 m3[8 hr]) / worker resp. volume (10 m3[8 hr])
Chronic = NOAEL = 2.3 mg/kg/day (NOAEL from 1 year rat study)
Corrected chronic NOAEC = 2.0 mg/m3
Dose response: the systemic effects observed in the chronic oral study were deemed to have a threshold mechanism. AF were applied according to the guidance in Chapter R.8.
AF: Default AFs were applied, according to the guidance in Chapter R.8 (note allometric scaling not relevant for the inhalatory route of exposure).
AF = Interspecies * Intraspecies (worker) * Exposure duration * Dose-response * Quality of whole database
AF = 2.5 * 5 * 1 * 1 *1 = 12.5
DNEL deviation: Corrected LOAEC / AF = 2.0 mg/m3/ 12.5
Chronic DNEL inhalation local & systemic = 0.2 mg/m3
Table 7-4:Chronic DNELs for workers
Endpoint Specific DNELs for Workers |
||||||
Endpoint |
Corrected dose-descriptor |
Overall AF |
Endpoint Specific DNEL |
|||
Local |
Systemic |
Local |
Systemic |
|||
Repeated dose toxicity sub-acute/ sub-chronic/ chronic |
Oral |
Not required |
Not required |
- |
- |
- |
dermal |
NOAEL |
NOAEL |
Local 12.5 Systemic 50 |
0.584 mg/cm2 |
20 mg/kg |
|
Inhalation (chronic) |
- |
NOAEC |
Local / Systemic |
0.16 mg/m3 |
0.16 mg/m3 |
|
General Population - Hazard via inhalation route
Systemic effects
Acute/short term exposure
DNEL related information
Local effects
Acute/short term exposure
DNEL related information
General Population - Hazard via dermal route
Systemic effects
Acute/short term exposure
DNEL related information
General Population - Hazard via oral route
Systemic effects
Acute/short term exposure
DNEL related information
General Population - Hazard for the eyes
Additional information - General Population
As the general population will not be exposed, DNEL considered unnecessary
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
